A 28-year-old woman presents to the antenatal clinic at 10 weeks of gestation with a 3-day history of low-grade fever, maculopapular rash on the face spreading downward, and mild arthralgia. Serological testing confirms acute rubella infection. Regarding the epidemiology and prevention of rubella in India, all of the following are true EXCEPT:

Explanation

## Rubella in Pregnancy: Epidemiology and Management in India ### Clinical Presentation and Diagnosis **Key Point:** The patient presents with the classic triad of rubella: fever, rash (maculopapular, starting on face and spreading downward), and arthralgia. Serological confirmation via IgM or IgG is the gold standard. ### Congenital Rubella Syndrome (CRS) Risk **High-Yield:** While the risk of CRS in the first trimester is 85–90%, termination of pregnancy is NOT the only management option. Management includes: 1. Counseling regarding the high risk of CRS 2. Continuation of pregnancy with informed consent 3. Close fetal monitoring (ultrasound for cardiac defects, growth restriction) 4. Postnatal surveillance and early intervention for detected defects 5. Termination is an option but NOT mandatory and depends on parental choice **Clinical Pearl:** Many countries, including India, do not mandate termination for rubella in early pregnancy; the decision is made after thorough counseling and informed consent. ### Notifiability in India **Key Point:** Rubella is a notifiable disease under the Integrated Disease Surveillance Programme (IDSP). All suspected and confirmed cases must be reported to the district surveillance officer within 24 hours. ### Immunization in India **High-Yield:** The MMR vaccine was introduced in India's Universal Immunization Programme (UIP) as a pilot in select states and is now being scaled up nationally. It is administered at 9–12 months of age. ### Immunity Assessment and Prevention **Key Point:** Rubella-specific IgG antibodies indicate immunity. Non-immune women of childbearing age should be vaccinated before conception (not during pregnancy, as MMR is a live vaccine). | Aspect | Details | | --- | --- | | CRS risk (1st trimester) | 85–90% | | CRS risk (2nd trimester) | 33–50% | | CRS risk (3rd trimester) | <10% | | Management approach | Counseling + informed choice (continuation or termination) | | Mandatory termination | No — decision is parental | | Immunity marker | Rubella-specific IgG | | Vaccination timing | Before conception (not in pregnancy) | **Warning:** The distractor claims termination is the ONLY management option, which is incorrect and ethically misleading. Continuation with informed consent and close monitoring is also a valid option.